Androgen-indifferent prostate cancer (AIPC) is a form of PCa with treatment-resistant phenotypes that do not rely on AR signaling and typically arise from mCRPC following treatment with ASIs [121,122], although they may arise de novo in treatment-naïve PCa [123,124]. The gene discussed is AR; the disease is prostate cancer.